Clinical Research in Southampton
Southampton Children's Hospital

A A A Text only | Accessibility | Privacy and cookies

Home
About the Trust
Our services
Patients and visitors
Our hospitals
Education
Research
Working here
Contact us

Browse site A to Z

A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z

Search results

Go To Advanced Search

Search

You could also try: accounts (204), files (86), paperwork (33)

STH816 v1 Department of infection user handbook

Description: Microbiology and Specialist Virology Services User Handbook STH816/02-25 Issued Date 23.07.2025 Authorised by R. Allen Page 1 of 48 Cont
Url: /Media/UHS-website-2019/Docs/Services/Pathology/STH816-v1-Department-of-infection-user-handbook.pdf

Whipple's procedure - patient information

Description: Your doctors have recommended that you have an operation called the Whipple's procedure. This is a complex operation to remove part
Url: /Media/UHS-website-2019/Patientinformation/Digestionandurinaryhealth/Whipples-procedure-3311-PIL.pdf

DRD Daratumumab-Lenalidomide-Dexamethasone

Description: Chemotherapy Protocol Myeloma DRD Daratumumab-Lenalidomide-Dexamethasone Regimen • Myeloma – DRD Daratumumab-Lenalidomide-Dexamethasone Indication • Daratumumab in combination with lenalidomide and dexamethasone
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Myeloma/DRD-Daratumumab-Lenalidomide-Dexamethasone.pdf

Preparing for surgery - patient information

Description: This booklet contains important information on how to prepare for surgery.
Url: /Media/UHS-website-2019/Patientinformation/Surgery/Preparing-for-surgery-3167-PIL.pdf

Carboplatin Paclitaxel EC Pembrolizumab Neoadjuvant Ver1.0

Description: Chemotherapy Protocol BREAST CANCER PEMBROLIZUMAB WITH CARBOPLATIN/PACLITAXEL AND EC NEOADJUVANT BREAST CANCER FOLLOWED BY ADJUVANT PEMBROLIZUMAB Regimen • Breast-Pembrolizumab with
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Breastcancer/Carboplatin-Paclitaxel-EC-Pembrolizumab-Neoadjuvant.pdf

Enhanced recovery after elective caesarean section - patient information

Description: This leaflet contains information about the recovery process after having a planned (elective) caesarean section.
Url: /Media/UHS-website-2019/Patientinformation/Pregnancyandbirth/Enhanced-recovery-after-elective-caesarean-section-1130-PIL.pdf

DVd-T SC Bortezomib-Daratumumab-Dexamethasone-Thalidomide v1

Description: Details of the Chemotherapy Protocol for Myeloma.
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Myeloma/DVd-T-SC-Bortezomib-Daratumumab-Dexamethasone-Thalidomide.pdf

DVdSC (weekly cycles1-8) Bortezomib-Daratumumab-Dexamethasone Ver1

Description: Chemotherapy Protocol Myeloma DVd SC (weekly cycles 1-8) Bortezomib-Daratumumab-Dexamethasone Regimen • Myeloma – DVd SC (weekly cycles 1-8) bortezomib
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Myeloma/DVdSC-weekly-cycles1-8-Bortezomib-Daratumumab-Dexamethasone-Ver1.pdf

Daratumumab SC Ver1

Description: Chemotherapy Protocol Myeloma Daratumumab Subcutaneous Regimen • Myeloma – Daratumumab (SC) Indication • Daratumumab monotherapy is recommended as an option for treating relapsed and
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Myeloma/Daratumumab-SC-Ver1.pdf

ObinutuzumabVenetoclax LowRisk

Description: Chemotherapy Protocol Chronic Lymphocytic Leukaemia Obinutuzumab-Venetoclax (Low Risk) Regimen • CLL – Obinutuzumab-Venetoclax (Low Risk) Indication • Chronic lymphatic leukaemia (CLL) or
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/CLL/ObinutuzumabVenetoclax-LowRisk.pdf

561 to 570 of 571

Previous … 54 55 56 57 58 Next